148 related articles for article (PubMed ID: 37843260)
1. Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?
Gatti M; Rinaldi M; Bonazzetti C; Gaibani P; Giannella M; Viale P; Pea F
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0096923. PubMed ID: 37843260
[TBL] [Abstract][Full Text] [Related]
2. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
[TBL] [Abstract][Full Text] [Related]
3. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF).
Gatti M; Rinaldi M; Gaibani P; Siniscalchi A; Tonetti T; Giannella M; Viale P; Pea F
J Crit Care; 2023 Aug; 76():154301. PubMed ID: 37059003
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant
Gatti M; Giannella M; Rinaldi M; Gaibani P; Viale P; Pea F
Antibiotics (Basel); 2022 Dec; 11(12):. PubMed ID: 36551398
[TBL] [Abstract][Full Text] [Related]
5. Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136770
[TBL] [Abstract][Full Text] [Related]
6. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections.
Fresan D; Luque S; Benítez-Cano A; Sorlí L; Milagro Montero M; De-Antonio M; Prim N; Vega V; Horcajada JP; Grau S
J Antimicrob Chemother; 2023 Mar; 78(3):678-683. PubMed ID: 36626402
[TBL] [Abstract][Full Text] [Related]
8. Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing
Gatti M; Bonazzetti C; Pascale R; Giannella M; Viale P; Pea F
Microorganisms; 2024 Jan; 12(1):. PubMed ID: 38257978
[TBL] [Abstract][Full Text] [Related]
9. A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections.
Gatti M; Tam VH; Gaibani P; Cojutti PG; Viale P; Pea F
Int J Antimicrob Agents; 2023 Apr; 61(4):106760. PubMed ID: 36804371
[TBL] [Abstract][Full Text] [Related]
10. A descriptive pharmacokinetic/pharmacodynamic analysis of ceftazidime-avibactam in a case series of critically ill patients with augmented renal clearance.
Xu Y; Tang J; Yuan B; Luo X; Liang P; Liu N; Dong D; Jin L; Ge W; Gu Q
Pharmacol Res Perspect; 2024 Feb; 12(1):e01163. PubMed ID: 38149723
[TBL] [Abstract][Full Text] [Related]
11. Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
Das S; Li J; Riccobene T; Carrothers TJ; Newell P; Melnick D; Critchley IA; Stone GG; Nichols WW
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670413
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
Sy SKB; Zhuang L; Sy S; Derendorf H
Clin Pharmacokinet; 2019 May; 58(5):545-564. PubMed ID: 30097887
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups.
Li J; Lovern M; Green ML; Chiu J; Zhou D; Comisar C; Xiong Y; Hing J; MacPherson M; Wright JG; Riccobene T; Carrothers TJ; Das S
Clin Transl Sci; 2019 Mar; 12(2):151-163. PubMed ID: 30221827
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections.
Berrino PM; Gatti M; Rinaldi M; Brunocilla E; Viale P; Pea F
Antibiotics (Basel); 2023 Aug; 12(9):. PubMed ID: 37760685
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run.
Gatti M; Viale P; Pea F
J Antimicrob Chemother; 2024 Jan; 79(1):195-199. PubMed ID: 38019676
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
18. Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration.
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887225
[TBL] [Abstract][Full Text] [Related]
19. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
20. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams.
Gatti M; Pea F
Expert Rev Anti Infect Ther; 2023 Feb; 21(2):149-166. PubMed ID: 36655779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
